A Review of Current Bipolar Disorder Treatment Guidelines

2012 ◽  
Vol 73 (03) ◽  
pp. e12 ◽  
Author(s):  
Alan Podawiltz
2015 ◽  
Vol 28 (2) ◽  
pp. 75-84 ◽  
Author(s):  
Louise Bjørklund ◽  
Henriette Thisted Horsdal ◽  
Ole Mors ◽  
Søren Dinesen Østergaard ◽  
Christiane Gasse

ObjectiveIn bipolar disorder, treatment with antidepressants without concomitant use of mood stabilisers (antidepressant monotherapy) is associated with development of mania and rapid cycling and is therefore not recommended. The present study aimed to investigate the psychopharmacological treatment patterns in bipolar disorder over time, with a focus on antidepressant monotherapy.MethodsCohort study with annual cross-sectional assessment of the use of psychotropic medications between 1995 and 2012 for all Danish residents aged 10 years or older with a diagnosis of bipolar disorder registered in the Danish Psychiatric Central Research Register. Users of a given psychotropic medication were defined as individuals having filled at least one prescription for that particular medication in the year of interest.ResultsWe identified 20 618 individuals with bipolar disorder. The proportion of patients with bipolar disorder using antidepressants, atypical antipsychotics and anticonvulsants increased over the study period, while the proportion of patients using lithium, typical antipsychotics and benzodiazepines/sedatives decreased. The proportion of patients treated with antidepressant monotherapy decreased from 20.5% in 1997 to 12.1% in 2012, and among antidepressant users, the proportion in monotherapy decreased from 47.7% to 23.9%, primarily driven by a decrease in the use of tricyclic antidepressants.ConclusionThe results show an increase in the proportion of patients with bipolar disorder being treated with antidepressants in the period from 1997 to 2012. However, in accordance with international treatment guidelines, the extent of antidepressant monotherapy decreased during the same period.


Author(s):  
Ives Cavalcante Passos ◽  
Flávio Kapczinski

It is known that if, not all, a substantial proportion of patients with bipolar disorder (BD) present a progressive course with functional and cognitive impairment. In addition, patients with BD and multiple mood episodes have a worse response to lithium and cognitive behaviour therapy. However, many current treatment guidelines do not take these clinical features that change with illness progression into account. In order to clarify these clinical questions, the term ‘neuroprogression’ was conceptualized as the pathological rewiring of the brain that takes place in parallel with the clinical deterioration in the course of BD. It provides a heuristic basis for conceptualizing the biochemical foundation of changes in brain circuits related to the progressive course of BD. Herein, we aim to review risk factors, biological underpinnings, and treatment implications related to neuroprogression in BD.


2009 ◽  
Author(s):  
Martha Sajatovic ◽  
William J. Meyer ◽  
Douglas Smith ◽  
Elizabeth Singer ◽  
Kristin A. Cassidy ◽  
...  

2018 ◽  
Vol 11 (9) ◽  
pp. dmm035600 ◽  
Author(s):  
Elizabeth Kelly ◽  
Devdutt Sharma ◽  
Christopher J. Wilkinson ◽  
Robin S. B. Williams

2010 ◽  
Vol 27 (5) ◽  
pp. 457-464 ◽  
Author(s):  
Stefanie A. Hlastala ◽  
Julie S. Kotler ◽  
Jon M. McClellan ◽  
Elizabeth A. McCauley

2018 ◽  
Vol 238 ◽  
pp. 666-673 ◽  
Author(s):  
Dominic Hodgkin ◽  
Maureen T. Stewart ◽  
Elizabeth L. Merrick ◽  
Ye Zhang Pogue ◽  
Noreen A. Reilly-Harrington ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document